Leveraging High- and Medium-Throughput Automation for Process Development at Merck / MSD

  • Reaction
  • 22 January 2026

About

Laboratory automation enables faster and more efficient data generation while minimizing material consumption. This presentation demonstrates how Merck’s Data Rich Experimentation group applies automated platforms to collect time course reaction profiles across different stages of drug development.

Three case studies will be presented which illustrate the versatility of our automation suite:

  1. Early Process Development: A custom Tecan Evo workflow was developed to profile monoclonal antibody (mAb) reduction kinetics, enabling detailed characterization during initial process design.
  2. Route Scouting: The ReactALL provided enhanced reaction insights that guided optimization decisions when evaluating synthetic routes.
  3. Tech Transfer: The ReactALL was deployed to de-risk a key impurity during technology transfer.

These examples demonstrate how tailored automation solutions can be strategically applied throughout the drug development lifecycle to generate high-quality time course data efficiently.

This webinar will be hosted by our partner ScientificUpdate and will take place on Thursday, 22nd of January, 2026 at the following time:

15.00   GMT (UK, Lisbon)
16.00   CET (Paris, Madrid, Frankfurt etc)
10.00   ET (New York, Boston)
7.00     PT (San Francisco, LA)

Speaker

Madeleine Deem

Senior Scientist, Data Rich Experimentation at Merck

Maddie earned her PhD in Chemistry from the University of British Columbia, conducting her research in Professor Jason Hein’s laboratory. During her doctoral studies, she utilized the lab’s custom automation platforms to generate data-rich reaction profiles and develop mechanistic understanding for complex transition metal-catalyzed processes. In 2023, Maddie joined the Data Rich Experimentation group at Merck, where she focuses on developing and deploying enabling technologies to support process development and characterization.